Follow the 삼성제약 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 삼성제약 has logged 19 public disclosures. The latest transaction was reported on 8 January 2026 (Other). Among the most active insiders: 젬백스. Every trade is openly available.
19
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
5 ops.
Sell Volume
7Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.